EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

Reverse transcriptase inhibitors in Aicardi–Goutières syndrome: A crossover clinical trial

Yanick J Crow iD, Tracy A Briggs, Despina Eleftheriou, Amitav Parida, Claire Battison, Annabel Giddings, Titouan Kennel, Richard A Parker, AGS‐RTIs Study Group

Developmental Medicine & Child Neurology · 2025-06 · 67 (6) · 750-757

DOI: 10.1111/dmcn.16199 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Developmental Medicine & Child Neurology, online erschienen am 04.12.2024. Verfasst von Yanick J Crow und 8 weiteren Autor:innen. Beteiligte Einrichtung: MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK. Hauptthemen laut MEDLINE: Autoimmune Diseases of the Nervous System, Nervous System Malformations, Reverse Transcriptase Inhibitors, Zidovudine. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Department of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To extend the findings of a previous clinical trial suggesting combined abacavir (ABC), lamivudine (3TC), and zidovudine (AZT) reduces type I interferon (IFN) signalling in Aicardi–Goutières syndrome (AGS).

Method

This was an open label, non‐placebo‐controlled phase II clinical trial (NCT04731103) in patients less than 16 years with any of five AGS genotypes. The effect of ABC or 3TC individually, or of combined ABC + 3TC + AZT, on IFN‐stimulated gene (ISG) expression (primary outcome) and IFN‐alpha protein (secondary outcome) in blood was assessed.

Results

Thirteen patients were recruited. Compliance was poor in the ABC + 3TC + AZT arm. No statistically significant effects were observed with ABC or 3TC, or with ABC + 3TC + AZT over 6 weeks. A statistically significant reduction of ISG expression was recorded after 3 weeks of ABC + 3TC + AZT, which was not mirrored by changes in IFN‐alpha protein.

Interpretation

There is insufficient evidence that ABC or 3TC is either effective or ineffective in reducing type I IFN signalling in AGS over 6 weeks. The effect of ABC + 3TC + AZT at 3 weeks supports data from a previous clinical trial of the effect of ABC + 3TC + AZT in reducing type I IFN signalling, although there was insufficient evidence of an effect at 6 weeks. Time to local research and development (R&D) approval, and to sponsor authorization after R&D approval, severely limited patient recruitment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Autoimmune Diseases of the Nervous SystemNervous System MalformationsReverse Transcriptase InhibitorsZidovudineLamivudineDideoxynucleosidesHumansMaleFemaleChildAdolescentCross-Over StudiesChild, PreschoolInterferon-alphaDrug Therapy, CombinationTreatment OutcomeCyclopropanesDideoxyadenosineAbacavir

Substanzen

Reverse Transcriptase InhibitorsZidovudineLamivudineDideoxynucleosidesInterferon-alphaCyclopropanesDideoxyadenosineAbacavir

Autor:innen und Institutionen

  • MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
  • Laboratory of Neurogenetics and Neuroinflammation, Imagine Institute, INSERM UMR1163, Paris, France.
  • Lydia Becker Institute of Immunology and Inflammation, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.
  • Department of Genomic Medicine, St Marys Hospital, Manchester Foundation Trust, Manchester, UK.
  • Division of Evolution, Infection and Genomics, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
  • Infection, Immunity and Inflammation Department, University College London Great Ormond Street Institute of Child Health, London, UK.

ORCID-Profile: Yanick J Crow

Förderung

  • Medical Research Council
  • Department of Health

Zitieren

APA

Crow, Y. J., Briggs, T. A., Eleftheriou, D., Parida, A., Battison, C., Giddings, A., Kennel, T., Parker, R. A., & AGS‐RTIs Study Group (2025). Reverse transcriptase inhibitors in Aicardi–Goutières syndrome: A crossover clinical trial. Developmental Medicine & Child Neurology, 67(6), 750-757. https://doi.org/10.1111/dmcn.16199

Vancouver

Crow YJ, Briggs TA, Eleftheriou D, Parida A, Battison C, Giddings A, et al. Reverse transcriptase inhibitors in Aicardi–Goutières syndrome: A crossover clinical trial. Developmental Medicine & Child Neurology. 2025;67(6):750-757. doi:10.1111/dmcn.16199

BibTeX
@article{Crow2025,
  author = {Crow, Yanick J and Briggs, Tracy A and Eleftheriou, Despina and Parida, Amitav and Battison, Claire and Giddings, Annabel and Kennel, Titouan and Parker, Richard A and AGS‐RTIs Study Group, AGS‐RTIs Study Group},
  title = {Reverse transcriptase inhibitors in Aicardi–Goutières syndrome: A crossover clinical trial},
  journal = {Developmental Medicine & Child Neurology},
  year = {2025},
  volume = {67},
  number = {6},
  pages = {750--757},
  doi = {10.1111/dmcn.16199}
}
Kostenlos starten →